Paper Details

  1. Home
  2. Paper Details

Long-term outcome of postremission chemotherapy for adults with acute myeloid leukemia using different dose-intensities.

Author: JehnU

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study evaluated different post-remission chemotherapy regimens for acute myeloid leukemia (AML) patients. Patients receiving intensive ablative maintenance (IM) had a median disease-free survival of 12.4 months, while those receiving intensive, short-term consolidation (IC) had a median of 18.4 months, both significantly better than the no-treatment group (3.3 months). Median survival was 20 months for IM, 47 months for IC, and 5.4 months for no further treatment. While there was a trend towards improved long-term survival with BMT in the IM group, long-term survival was similar for IC regardless of BMT. The study concludes that increasing the intensity of post-remission therapy progressively improves remission duration and survival in AML patients.
Paper Details　
Original Abstract of the Article :
The long-term results of postremission chemotherapy for 122 consecutive, unselected adults (15-65 years) with acute myeloid leukemia (AML) were assessed in two sequential prospective studies involving an identical 3/7-type induction regimen, and in those achieving remission, another course for early...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.3109/10428199409051684

データ提供：米国国立医学図書館（NLM）

Postremission Chemotherapy for AML: A Journey Through the Desert of Cancer

This study takes us on a journey through the vast and challenging desert of acute myeloid leukemia (AML), a serious form of blood cancer. We explore the effectiveness of different postremission chemotherapy regimens, like navigating various paths through the desert, seeking the most effective route to a cure.

The researchers analyzed the long-term outcomes of two different postremission chemotherapy approaches, focusing on their impact on disease-free survival (DFS) and overall survival. This is like comparing two groups of travelers, each taking a different path through the desert, to see which route offers the best chance of reaching a safe destination.

Graded Success: Increased Intensity, Enhanced Survival

The study revealed a significant improvement in DFS and survival with increased intensity of postremission chemotherapy. It's like finding a path with more resources and support, leading to a greater chance of success in crossing the desert.

Navigating the Desert of Cancer: A Choice of Paths

This study underscores the importance of choosing the right path for postremission chemotherapy, carefully considering the risks and benefits of each approach. It's like choosing the right camel for your desert journey, selecting the one most likely to lead you to a safe and successful destination.

Dr. Camel's Conclusion

This study, like a map charting the treacherous terrain of AML, highlights the importance of tailoring treatment strategies to optimize outcomes. It underscores the need for continued research and innovation in this field, guiding us towards a brighter future for those battling this challenging disease.

Date :
  1. Date Completed 1995-03-20
  2. Date Revised 2019-01-16
Further Info :

Pubmed ID

7532060

DOI: Digital Object Identifier

10.3109/10428199409051684

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.